ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Short Interest Update

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) was the recipient of a large decline in short interest in the month of January. As of January 15th, there was short interest totalling 2,150,000 shares, a decline of 8.5% from the December 31st total of 2,350,000 shares. Based on an average daily volume of 252,300 shares, the short-interest ratio is currently 8.5 days.

ANI Pharmaceuticals Stock Down 1.5 %

Shares of ANIP stock traded down $0.92 during trading hours on Friday, reaching $58.64. The company had a trading volume of 119,741 shares, compared to its average volume of 159,698. The company has a market cap of $1.23 billion, a price-to-earnings ratio of -106.62 and a beta of 0.73. The company has a debt-to-equity ratio of 1.52, a current ratio of 2.74 and a quick ratio of 1.97. ANI Pharmaceuticals has a 12 month low of $52.50 and a 12 month high of $70.81. The business has a fifty day simple moving average of $56.61 and a 200-day simple moving average of $58.60.

ANI Pharmaceuticals (NASDAQ:ANIP) last issued its quarterly earnings data on Friday, November 8th. The specialty pharmaceutical company reported $1.34 earnings per share for the quarter, beating the consensus estimate of $1.09 by $0.25. The business had revenue of $148.30 million for the quarter, compared to analysts’ expectations of $144.37 million. ANI Pharmaceuticals had a positive return on equity of 15.87% and a negative net margin of 1.28%. The business’s revenue was up 12.5% on a year-over-year basis. During the same period last year, the business earned $1.05 EPS. On average, research analysts expect that ANI Pharmaceuticals will post 3.86 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms have commented on ANIP. StockNews.com cut shares of ANI Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday. Truist Financial raised their target price on ANI Pharmaceuticals from $60.00 to $62.00 and gave the company a “hold” rating in a research note on Tuesday, October 22nd. Piper Sandler assumed coverage on ANI Pharmaceuticals in a research note on Friday, October 11th. They set an “overweight” rating and a $68.00 price target on the stock. Leerink Partners initiated coverage on ANI Pharmaceuticals in a research note on Wednesday, December 11th. They issued an “outperform” rating and a $80.00 price objective for the company. Finally, HC Wainwright restated a “buy” rating and set a $94.00 price objective on shares of ANI Pharmaceuticals in a report on Monday, November 11th. One investment analyst has rated the stock with a sell rating, one has given a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, ANI Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus price target of $77.71.

Insider Transactions at ANI Pharmaceuticals

In other ANI Pharmaceuticals news, CFO Stephen P. Carey sold 7,500 shares of the business’s stock in a transaction that occurred on Tuesday, December 17th. The stock was sold at an average price of $55.79, for a total value of $418,425.00. Following the transaction, the chief financial officer now directly owns 154,468 shares of the company’s stock, valued at approximately $8,617,769.72. The trade was a 4.63 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Nikhil Lalwani sold 33,481 shares of the firm’s stock in a transaction that occurred on Tuesday, November 26th. The stock was sold at an average price of $57.99, for a total transaction of $1,941,563.19. Following the sale, the chief executive officer now directly owns 370,378 shares of the company’s stock, valued at approximately $21,478,220.22. This trade represents a 8.29 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 42,381 shares of company stock worth $2,441,556. Company insiders own 12.70% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the stock. KBC Group NV boosted its position in shares of ANI Pharmaceuticals by 89.2% in the fourth quarter. KBC Group NV now owns 1,273 shares of the specialty pharmaceutical company’s stock valued at $70,000 after acquiring an additional 600 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in ANI Pharmaceuticals by 24.2% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,971 shares of the specialty pharmaceutical company’s stock worth $177,000 after purchasing an additional 579 shares in the last quarter. HighTower Advisors LLC bought a new position in ANI Pharmaceuticals in the 3rd quarter valued at $222,000. Susquehanna Fundamental Investments LLC purchased a new position in shares of ANI Pharmaceuticals during the 2nd quarter valued at $228,000. Finally, China Universal Asset Management Co. Ltd. increased its holdings in shares of ANI Pharmaceuticals by 64.2% in the third quarter. China Universal Asset Management Co. Ltd. now owns 4,045 shares of the specialty pharmaceutical company’s stock worth $241,000 after purchasing an additional 1,582 shares during the period. Hedge funds and other institutional investors own 76.05% of the company’s stock.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.